当前位置: X-MOL 学术Diabetes › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Potential Protection Against Type 2 Diabetes in Obesity Through Lower CD36 Expression and Improved Exocytosis in β-Cells
Diabetes ( IF 7.7 ) Pub Date : 2020-03-20 , DOI: 10.2337/db19-0944
Mototsugu Nagao 1, 2 , Jonathan L S Esguerra 3 , Akira Asai 2, 3, 4 , Jones K Ofori 3 , Anna Edlund 3 , Anna Wendt 3 , Hitoshi Sugihara 2 , Claes B Wollheim 5 , Shinichi Oikawa 2 , Lena Eliasson 1
Affiliation  

Obesity is a risk factor for type 2 diabetes (T2D); however, not all obese individuals develop the disease. In this study, we aimed to investigate the cause of differential insulin secretion capacity of pancreatic islets from donors with T2D and non-T2D (ND), especially obese donors (BMI ≥30 kg/m2). Islets from obese donors with T2D had reduced insulin secretion, decreased β-cell exocytosis, and higher expression of fatty acid translocase CD36. We tested the hypothesis that CD36 is a key molecule in the reduced insulin secretion capacity. Indeed, CD36 overexpression led to decreased insulin secretion, impaired exocytosis, and reduced granule docking. This was accompanied by reduced expression of the exocytotic proteins SNAP25, STXBP1, and VAMP2, likely because CD36 induced downregulation of the insulin receptor substrate (IRS) proteins, suppressed the insulin-signaling phosphatidylinositol 3-kinase/AKT pathway, and increased nuclear localization of the transcription factor FoxO1. CD36 antibody treatment of the human β-cell line EndoC-βH1 increased IRS1 and exocytotic protein levels, improved granule docking, and enhanced insulin secretion. Our results demonstrate that β-cells from obese donors with T2D have dysfunctional exocytosis likely due to an abnormal lipid handling represented by differential CD36 expression. Hence, CD36 could be a key molecule to limit β-cell function in T2D associated with obesity.

中文翻译:

通过降低 CD36 表达和改善 β 细胞的胞吐作用,对肥胖患者的 2 型糖尿病具有潜在保护作用

肥胖是 2 型糖尿病 (T2D) 的危险因素;然而,并非所有肥胖者都会患上这种疾病。在本研究中,我们旨在调查 T2D 和非 T2D (ND) 供体,尤其是肥胖供体 (BMI ≥ 30 kg/m2) 胰岛胰岛素分泌能力差异的原因。来自患有 T2D 的肥胖供体的胰岛具有减少的胰岛素分泌、减少的 β 细胞胞吐作用和更高的脂肪酸转位酶 CD36 表达。我们检验了 CD36 是降低胰岛素分泌能力的关键分子的假设。事实上,CD36 过表达导致胰岛素分泌减少、胞吐作用受损和颗粒对接减少。这伴随着胞吐蛋白 SNAP25、STXBP1 和 VAMP2 的表达降低,可能是因为 CD36 诱导了胰岛素受体底物 (IRS) 蛋白的下调,抑制胰岛素信号磷脂酰肌醇 3-激酶/AKT 通路,并增加转录因子 FoxO1 的核定位。人 β 细胞系 EndoC-βH1 的 CD36 抗体处理增加了 IRS1 和胞吐蛋白水平,改善了颗粒对接,并增强了胰岛素分泌。我们的结果表明,来自患有 T2D 的肥胖供体的 β 细胞具有功能失调的胞吐作用,这可能是由于以差异 CD36 表达为代表的异常脂质处理。因此,CD36 可能是限制与肥胖相关的 T2D 中 β 细胞功能的关键分子。并增强胰岛素分泌。我们的结果表明,来自患有 T2D 的肥胖供体的 β 细胞具有功能失调的胞吐作用,这可能是由于以差异 CD36 表达为代表的异常脂质处理。因此,CD36 可能是限制与肥胖相关的 T2D 中 β 细胞功能的关键分子。并增强胰岛素分泌。我们的结果表明,来自患有 T2D 的肥胖供体的 β 细胞具有功能失调的胞吐作用,这可能是由于以差异 CD36 表达为代表的异常脂质处理。因此,CD36 可能是限制与肥胖相关的 T2D 中 β 细胞功能的关键分子。
更新日期:2020-03-20
down
wechat
bug